These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 22487814)
1. Late subcapsular lymphocele in a kidney graft. Mestres J; Sebastià C; Musquera M; Paño B; Peri L; Alcaraz A; Nicolau C Transplantation; 2012 Apr; 93(8):e35-7. PubMed ID: 22487814 [No Abstract] [Full Text] [Related]
2. Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? De Simone C; Caldarola G; Castriota M; Salerno MP; Citterio F Eur J Dermatol; 2012; 22(2):280-1. PubMed ID: 22381670 [No Abstract] [Full Text] [Related]
3. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial. Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603 [TBL] [Abstract][Full Text] [Related]
4. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841 [TBL] [Abstract][Full Text] [Related]
5. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Pratap B; Abraham G; Srinivas CN; Bhaskar S Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):609-12. PubMed ID: 17951952 [TBL] [Abstract][Full Text] [Related]
7. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302 [TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
9. Donor pretreatment of grafts from marginal donors improves long-term graft outcome. Reutzel-Selke A; Tullius SG; Zschockelt T; Nieminen-Kelhä M; Bachmann U; Jonas S; Pratschke J; Schmidbauer G; Bechstein WO; Volk H; Neuhaus P Transplant Proc; 2001; 33(1-2):970-1. PubMed ID: 11267150 [No Abstract] [Full Text] [Related]
10. Combined sirolimus-calcineurin inhibitor immunosuppressive therapy in simultaneous heart and kidney transplantation: a retrospective analysis of a single hospital's experience. Hsu KH; Chou NK; Tsai MK; Chi NH; Chen YS; Yu HY; Wang CH; Ko WJ; Tsao CI; Lee PH; Wang SS Transplant Proc; 2010 Apr; 42(3):934-7. PubMed ID: 20430208 [TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Holmes M; Chilcott J; Walters S; Whitby S; Akehurst R Transpl Int; 2004 May; 17(4):182-7. PubMed ID: 15107971 [TBL] [Abstract][Full Text] [Related]
13. Correlations with six-month protocol biopsy findings in pediatric transplant recipients on low- and regular-dose CNI regimens. Kanzelmeyer NK; Ahlenstiel T; Kreuzer M; Becker JU; Pape L Clin Transplant; 2013; 27(2):319-23. PubMed ID: 23414365 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Lorber MI; Ponticelli C; Whelchel J; Mayer HW; Kovarik J; Li Y; Schmidli H Clin Transplant; 2005 Apr; 19(2):145-52. PubMed ID: 15740547 [TBL] [Abstract][Full Text] [Related]
16. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. González E; Andrés A; Polanco N; Hernández A; Morales E; Hernandez E; Huerta A; Ortuño T; Gutiérrez Martínez E; Praga M; Morales JM Transplant Proc; 2009; 41(6):2332-3. PubMed ID: 19715911 [TBL] [Abstract][Full Text] [Related]
17. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation? Kandaswamy R; Dunn T; Humar A; Sutherland DE Transplant Proc; 2008 Mar; 40(2):516-7. PubMed ID: 18374118 [No Abstract] [Full Text] [Related]